Background {#Sec1}
==========

Upper gastrointestinal bleeding in cirrhotic patients is associated with an increased rate of failure to control bleeding and can result in mortality when bacterial infections occur \[[@CR1], [@CR2]\]. This is evidenced by reports demonstrating that oral administration of non-absorbable antibiotics markedly reduces the incidence of bacterial infections in cirrhotic patients with gastrointestinal hemorrhage \[[@CR3]\]. Patients with cirrhosis are at risk for both variceal and nonvariceal causes of upper gastrointestinal bleeding; however, only variceal bleeding has been widely studied. Nevertheless, there remains one third of nonvariceal upper gastrointestinal bleeding in cirrhotic patients due to peptic ulcers (PU) as reported in the literature \[[@CR4]\]. In addition, bleeding PU have been associated with substantial morbidity and mortality in cirrhotic patients \[[@CR5]\]. A multicenter prospective study from Italy reported that 10 % of patients with cirrhosis rebleed and 15 % of them died within 6 weeks after acute nonvariceal upper gastrointestinal bleeding \[[@CR5]\].

Bacterial infection is more prone to initiate a systemic inflammatory response syndrome and increases the probability of death in patients with decompensated cirrhosis \[[@CR6]\]. Generally, cirrhotic patients with PUB become infected and rebleed more frequently compared to non-cirrhotic patients \[[@CR4]\]. To our knowledge, prognosis after treating acute PUB has not been well studied in cirrhotic patients. Most studies on antibiotic prophylaxis in cirrhotic patients have focused on those with variceal hemorrhages \[[@CR7]--[@CR9]\]. Therefore, we conducted this study to identify the risk factors that predict re-bleeding, bacterial infections, mortality and the impact of antibiotic prophylaxis on death at different stages of cirrhosis following acute PUB.

Methods {#Sec2}
=======

Ethics statements {#Sec3}
-----------------

This retrospective chart review study was approved by both the Institutional Review Board and Ethics Committee of Chang Gung Memorial Hospital, Taiwan (IRB103-5018B). The Ethics Committee waived the requirement for informed consent, and each patient's medical records was anonymized and de-identified prior to access. All patients provided their written inform consent before endoscopic interventions.

Patient population {#Sec4}
------------------

This was a hospital-based retrospective cohort study including 426 cirrhotic eligible patients with PUB who underwent endoscopic interventions over a 6 year period between January 2008 and January 2014. The following patients were excluded from the study: (1) presence of any of the following signs of infection; fever \>38 °C, white blood cell count \>10 000/mm^3^, immature neutrophils \>500/mm^3^, a polymorphonuclear cell count in ascitic fluid \>250/mm^3^, ≥15 leukocytes/field in the fresh urine sediment, or data compatible with pneumonia on the chest X-ray (*n* = 105), (2) allergy to cephalosporins (*n* = 2), (3) patients who received oral/parenteral antibiotics in the week prior to the procedure (*n* = 18), (4) a source of upper gastrointestinal bleeding other than PUB (*n* = 37), (5) patients who died within the first day after admission (*n* = 3), (6) patients who did not complete the in-hospital follow-up period (*n* = 26). A total of 235 patients were recruited into current study (male/female: 181/54; mean age: 62.2 ± 13.6 y). Those patients who received prophylactic intravenous infusion of ceftriaxone at 1 g per 12 h were classified as the antibiotic group (*n* = 88) in contrast to the control group who did not receive antibiotics (*n* = 147). The antibiotic group has been routine practice to prescribe prophylactic antibiotics to cirrhotic patients with gastrointestinal bleeding in our hospital since the year 2010 according to guidelines. On the other hand, those patients belonged to control group attended the hospital between January 2008 and December 2009. The antibiotic prophylaxis was given immediately after patients receiving endoscopic treatment and two sets of blood culture were obtained before administering the antibiotics even these patients did not encounter infections according to our hospital policy.

PUB was defined by the existence of signs of hematemesis, coffee ground vomitus, hematochezia, or melena and proven high-risk ulcers by endoscopy that were defined according to the Forrest classification \[[@CR10]\]. High risk bleeding stigmata were referred for endoscopic view of active bleeding, visible vessels, or adherent clots. Patients' performance status was stratified according to the Rockall classification \[[@CR11]\]. Blood transfusions were given to maintain hematocrit levels between 25 % and 30 %. Patients with PUB were treated with intravenous high dose pantoprazole (80 mg intravenous bolus followed by 200 mg continuous infusion for three days).

Data collection and analysis {#Sec5}
----------------------------

The first authors abstracted following information from patient records (including written charts and electronic data sources). All patients had a complete medical assessment at initial hospital admission, including documentation of clinical, biochemical, and endoscopic factors that might contribute to rebleeding and mortality. The registered clinical variables were demographic data, clinical manifestations of bleeding, and the use of tobacco, alcohol, aspirin, clopidogrel, and non-steroidal anti-inflammatory drugs (NSAID); co-morbidities such as diabetes mellitus, cardiovascular disease, stroke, end-stage renal disease, and chronic pulmonary disease were analyzed. Other clinical characteristics such as age, sex, and hemodynamic instability on admission and laboratory data such as white blood cell count, hemoglobin, platelet count, prothrombin time, serum creatinine, serum albumin, and total bilirubin were analyzed. The recorded endpoints were occurrence of infection, rebleeding, length of hospital stay, and in-hospital death.

Definitions {#Sec6}
-----------

Time to endoscopy was defined as the time interval from admission via the emergency department to initial endoscopy, expressed in hours. The diagnosis of liver cirrhosis was based on clinical, laboratory, abdominal ultrasonographic, or histological findings \[[@CR12]\]. Decompensated liver cirrhosis was used to describe patients complicated by ascites, jaundice (bilirubin level \>3.0 mg/dl), and a history of identified varices or hepatic encephalopathy. Diagnosis of hepatitis C and B virus-related liver disease was determined with specific viral markers (HBsAg or anti-HCV). Alcohol-related liver disease was defined as daily alcohol consumption \>80 g in men and \>40 g in women for at least 10 years with negative viral, metabolic, and autoimmune markers \[[@CR13]\]. Active alcoholism is defined as a continuing daily alcohol intake over 20 g in patients with alcoholic cirrhosis \[[@CR13]\].

Rebleeding was defined as a new onset of hematemesis, melena, or both associated with tachycardia or hypovolemic shock or a decrease in serum hemoglobin level of \>2 g/dl after successful endoscopic and pharmacological treatment and hemodynamic stability of at least a 24 h period of stable vital signs \[[@CR14]\].

A diagnosis of bacteremia was made when the presence of viable bacteria in the blood and the clinical picture was consistent with this diagnosis. The diagnosis of spontaneous bacterial peritonitis was made when a positive culture of ascitic fluid was obtained with an ascitic fluid neutrophil count ≥250 neutrophils/μl \[[@CR15]\]. The diagnosis of pneumonia was made by clinical, radiological, and bacteriological data. The diagnosis of urinary tract infection was made when a positive culture of urine (10^5^ ≥ colonies/ml) was obtained with a urine neutrophil count \>10 neutrophils/μl and associated clinical pictures.

Statistical analysis {#Sec7}
--------------------

All results were expressed as means ± standard deviations for continuous variables and as relative frequencies or percentages for categorical variables. Distributions of continuous variables were analyzed by the X^2^ test, the Fisher's exact test, or the independent sample *t*-test, depending upon the type of data analyzed for the two groups where appropriate. The Kaplan--Meier analysis with the log-rank test was used to compare differences of death rates between the two groups. Variables were analyzed using the multivariate Cox proportional hazard model to determine independent predictive factors of infection, rebleeding, and mortality. All the variables in univariate analyses were analyzed in multivariate analyses. The results were expressed as a hazard ratio (HR) with 95 % confidence intervals. All statistical analyses were performed using the SPSS v18.0 (Chicago, Illinois, USA). A *p*-value of \<0.05 was considered statistically significant.

Results {#Sec8}
=======

All the patients' baseline characteristics are presented in Table [1](#Tab1){ref-type="table"}. All patients underwent emergency endoscopy within 24 h of admission. The mean time from presentation of bleeding to endoscopy was 7.6 ± 7 h. One hundred and forty-six patients (62.1 %) suffered from bleeding gastric ulcers (GU), 73 (31.1 %) from duodenal ulcers (DU), and 16 (6.8 %) from both GU and DU. These ulcers had high risk stigmata of hemorrhage (Forrest Ia or Ib, 50.2 % and Forrest II a or IIb, 38.7 %). Among them, 57.4 % were found to have varices without stigmata of recent hemorrhage \[esophageal varices (EV): 51.4 %; gastric varices (GV): 0.9 %; combined EV/GV: 5.1 %\]. The mean value of the Rockall scoring system was 4.7 ± 1.6 on admission.Table 1Clinical characteristics, endoscopic findings, and clinical outcome of cirrhotic patients with peptic ulcer bleeding (*n* = 235)CharacteristicsAntibiotic group (*n* = 88)Control group (*n* = 147)*p*-valueAge (y)61.8 ± 15.262.5 ± 12.50.699Male, n (%)71 (80.7)110 (74.8)0.302Etiology of liver cirrhosis  Alcoholic, n (%)24 (27.3)37 (25.2)0.722  Viral hepatitis, n (%)62 (70.4)100 (68.0)0.697  Cryptogenic, n (%)2 (2.3)10 (6.8)0.219Child-Pugh group  A, n (%)40 (45.5)68 (46.3)0.905  B, n (%)31 (35.2)44 (29.9)0.399  C, n (%)17 (19.3)35 (23.8)0.422Decompensated cirrhosis, n (%)44 (50.0)61 (41.5)0.204Rockall score4.7 ± 1.54.7 ± 1.70.885MELD score13.7 ± 6.114.1 ± 6.00.631Child-Pugh score6.9 ± 1.57.1 ± 1.70.467Gastroesophageal varices, n (%)51 (58.0)84 (57.1)0.903Ulcer location  Gastric ulcer, n (%)55 (62.5)91 (61.9)0.927  Duodenal ulcer, n (%)27 (30.7)46 (31.3)0.922  Both, n (%)6 (6.8)10 (6.8)1Use of NSAID or aspirin/clopidogrel, n (%)17 (19.3)20 (13.6)0.245Smoking, n (%)33 (37.5)63 (42.9)0.419Active alcoholism, n (%)31 (35.2)55 (37.4)0.736Other comorbidities  Diabetes mellitus, n (%)31 (35.2)40 (27.2)0.251  Hypertension, n (%)39 (44.3)54 (36.7)0.311  Cardiovascular disease, n (%)8 (9.1)7 (4.8)0.299  Stroke, n (%)3 (3.4)10 (6.8)0.381  ESRD, n (%)3 (3.4)13 (8.8)0.471  COPD, n (%)8 (9.1)7 (4.8)0.269Laboratory on admission  WBC (10^9^/l)6094.3 ± 2045.35876.2 ± 1970.40.419  Hb (g/dl)8.7 ± 2.58.9 ± 1.90.437  PLT (10^9^/l)124.5 ± 60.5121.5 ± 71.30.731  Prothrombin time (s)13.6 ± 4.812.4 ± 2.70.031  Albumin (g/dl)3.0 ± 0.72.8 ± 0.70.152  Creatinine (mg/dl)1.6 ± 2.02.0 ± 2.50.126  Total bilirubin (mg/dl)3.0 ± 3.83.1 ± 3.80.961Clinical characteristics  Hypovolemic shock on admission, n (%)8 (9.1)13 (8.8)0.949  Blood units transfused (unit)4.8 ± 5.65.2 ± 7.60.637Stigmata of recent hemorrhage at ulcer  Forrest Ia or Ib ulcer, n (%)44 (50)74 (50.3)0.960  Forrest IIa or IIb ulcer, n (%)37 (42)54 (36.7)0.419  Forrest IIc ulcer, n (%)7 (8)19 (13)0.240Time (h), bleeding to endoscopic treatment6.9 ± 6.77.7 ± 6.60.382Treatment  Epinephrine injection, n (%)27 (30.7)57 (38.8)0.261  APC, n (%)13 (14.8)37 (25.2)0.070  Hemoclipping, n (%)14 (15.9)6 (4.1)0.003  Combined therapy, n (%)34 (38.6)47 (32.0)0.323Outcomes  Hospital stay (d)15.7 ± 13.114.1 ± 10.90.282  Rebleeding, n (%)3 (3.4)45 (30.6)\<0.001  Infections, n (%)9 (10.2)37 (25.2)0.005  In-hospital mortality, n (%)12 (13.6)28 (19.0)0.112  Failure to control bleeding, n (%)1 (1.1)7 (4.8)  Sepsis, n (%)3 (3.4)7 (4.8)  Multiple organ failure, n (%)8 (9.1)14 (9.4)Abbreviations: *APC*, argon plasma coagulation; *COPD*, chronic obstructive pulmonary disease; *ESRD*, end-stage renal disease; *EV*, esophageal varices; *GOV*, Gastroesophageal varices; *IGV*, Isolated gastric varices; *MELD*, Model for End-Stage Liver Disease; *NSAID*, nonsteroidal anti-inflammatory drug; *WBC*, white blood cells; *Hb*, hemoglobin; *PLT*, platelet count; *PT*, prothrombin time

The details of endoscopic interventions are also summarized in Table [1](#Tab1){ref-type="table"}. Endoscopic intervention was performed on all patients with either monotherapy (65.5 %) or combination therapy (34.5 %). All patients received intravenous high dose proton pump inhibitors for 3 days after initial endoscopic hemostasis. The mean length of hospital stay was 14.9 ± 11.6 d. Patients in the antibiotic group had a similar hospital stay when compared with control patients (*p* = 0.282).

Overall, 48 (20.4 %) patients encountered rebleeding events. Rebleeding rate in the antibiotic group was significantly lower than the control group (3.4 % vs 30.6 %; p \<0.001; Table [1](#Tab1){ref-type="table"}). On multivariate analysis, the risk factors for rebleeding were higher rockall score \[HR = 1.069; 95 % confidence interval (CI) = 1.022--1.120; *p* = 0.004\] and more units of blood transfusion (HR = 1.019; 95 % CI = 1.002--1.037; *p* = 0.031). Antibiotic prophylaxis has a protective role for rebleeding in these patients (HR = 0.082; 95 % CI = 0.025--0.267; p \<0.001) (Table [2](#Tab2){ref-type="table"}). It is interesting that time to endoscopy, high risk bleeding stigmata, and endoscopic therapeutic methods were not associated with rebleeding rate (Table [2](#Tab2){ref-type="table"}).Table 2Univariate and multivariate analysis of potential risk factors for rebleeding in patients with peptic ulcer bleeding after endoscopic treatmentVariableUnivariate analysisMultivariate analysisHazard ratio (95 % CI)*p*-valueHazard ratio (95 % CI)*p*-valueAge0.991 (0.971--1.012)0.383Male gender2.882 (1.141--7.283)0.0252.639 (0.968--7.198)0.058Etiology of liver cirrhosis  Alcoholic1.001 (0.521--1.924)0.998  Viral hepatitis1.086 (0.790--1.494)0.610  Cryptogenic0.715 (0.369--1.384)0.319Decompensated cirrhosis1.559 (0.881--2.758)0.127Rockall score1.071 (1.031--1.111)\<0.0011.069 (1.022--1.120)0.004MELD score1.141 (0.964--1.351)0.126Child-Pugh score1.321 (1.126--1.548)0.0011.128 (0.923--1.378)0.238Other comorbidities  Diabetes mellitus1.244 (0.689--2.249)0.469  Hypertension0.688 (0.378--1.255)0.233  CVD0.948 (0.230--3.912)0.941  Stroke1.360 (0.422--4.382)0.607  ESRD1.246 (0.448--3.470)0.673  COPD0.495 (0.145--1.683)0.260Use of NSAID or aspirin1.479 (0.586--3.734)0.408Smoking1.362 (0.771--2.405)0.287Active alcoholism1.585 (0.898--2.799)0.112WBC (10^9^/l)10.886Hb (g/dl)0.990 (0.869--1.128)0.880PLT (10^9^/l)0.997 (0.992--1.002)0.260PT (s)1.286 (0.749--2.207)0.362Creatinine (mg/dl)1.063 (0.966--1.171)0.213Albumin (g/l)0.635 (0.402--1.005)0.053Total bilirubin1.068 (1.012--1.128)0.0171.042 (0.967--1.122)0.277Blood units transfused1.032 (1.015--1.050)\<0.0011.019 (1.002--1.037)0.031Hypovolemic shock on admission1.143 (0.453--2.887)0.777High risk bleeding stigmata at ulcer base1.103 (0.407--2.989)0.848Time (h), bleeding to endoscopic treatment0.989 (0.959--1.039)0.940Combined treatment of endoscopic hemostasis0.941 (0.521--1.700)0.840Bacterial infection1.974 (1.081--3.607)0.0271.012 (0.527--1.941)0.972Antibiotic prophylaxis0.090 (0.028--0.291)\<0.0010.082 (0.025--0.267)\<0.001Abbreviations: *CI*, confidence interval; *COPD*, chronic obstructive pulmonary disease; *CVD*, Cardiovascular disease; *ESRD*, end-stage renal disease; *MELD*, Model for End-Stage Liver Disease; *NSAID*, nonsteroidal anti-inflammatory drug; *WBC*, white blood cells; *Hb*, hemoglobin; *PLT*, platelet count; *PT*, prothrombin time

Bacterial infections were documented in 46 patients (19.6 %); more patients were infected in the control group (10.2 % vs. 25.2 %; *p* = 0.005). Infections were confirmed for 9 patients in the antibiotics group (bacteremia in 4, spontaneous bacterial peritonitis in 2, pneumonia in 1 and urinary tract infection in 2). On the other hand, 37 bacterial infections were proven in the control group (bacteremia in 17, pneumonia in 4, spontaneous bacterial peritonitis in 10, and urinary tract infections in 6). The causative organisms of bacteremia were gram-negative bacilli in 15 patients (*Klebsiella pneumoniae* in 7; *Escherichia coli* in 6; *Pseudomonas aeruginosa* in 2) and gram-positive cocci in 6 patients (*Streptococcus pneumoniae* in 4; *Staphylococcus aureus* in 1; *Enterococcus faecalis* in 1). The risk factors for bacterial infection were higher Child-Pugh score (HR = 1.251; 95 % CI = 1.080--1.449; *p* = 0.003) and active alcoholism (HR = 1.882; 95 % CI = 1.045--3.388; *p* = 0.035). Antibiotic prophylaxis played a significant role to prevent infections (HR = 0.377; 95 % CI = 0.180--0.786; *p* = 0.009) (Table [3](#Tab3){ref-type="table"}).Table 3Univariate and multivariate analysis of potential risk factors for infection in patients with peptic ulcer bleeding after endoscopic treatmentVariableUnivariate analysisMultivariate analysisHazard ratio (95 % CI)*p*-valueHazard ratio (95 % CI)*p*-valueAge0.989 (0.968--1.010)0.286Male gender1.171 (0.580--2.363)0.660Etiology of liver cirrhosis  Alcoholic1.869 (1.015--3.441)0.0451.842 (0.899--3.774)0.095  Viral hepatitis0.769 (0.572--1.035)0.083  Cryptogenic0.933 (0.582--1.498)0.775Decompensated cirrhosis2.339 (1.273--4.298)0.0061.688 (0.707--4.043)0.239Rockall score1.275 (1.048--1.552)0.0151.141 (0.944--1.381)0.173MELD score1.061 (1.022--1.100)0.0021.048 (0.988--1.111)0.121Child-Pugh score1.289 (1.113--1.493)0.0011.251 (1.080--1.449)0.003Other comorbidities  Diabetes mellitus1.272 (0.693--2.338)0.437  Hypertension0.971 (0.537--1.757)0.923  CVD0.483 (0.066--3.510)0.472  Stroke0.412 (0.057--2.990)0.380  ESRD1.661 (0.402--6.860)0.483  COPD1.981 (0.837--4.686)0.120Use of NSAID or aspirin0.127 (0.018--0.925)0.0420.182 (0.025--1.336)0.094Smoking1.301 (0.725--2.335)0.378Active alcoholism1.924 (1.075--3.446)0.0281.616 (0.789--3.310)0.190WBC (10^9^/l)10.804Hb (g/dl)0.899 (0.775--1.019)0.090PLT (10^9^/l)0.996 (0.991--1.001)0.160PT (second)1.290 (0.781--2.129)0.319Creatinine (mg/dl)0.958 (0.830--1.106)0.562Albumin (g/l)0.921 (0.592--1.434)0.716Total bilirubin1.071 (1.019--1.127)0.0081.006 (0.929--1.088)0.887Blood units transfused1.016 (0.993--1.01400.181Hypovolemic shock on admission1.328 (0.525--3.362)0.550High risk bleeding stigmata at ulcer base2.830 (0.686--11.68)0.150Time (h), bleeding to endoscopic treatment1.026 (0.997--1.055)0.077Combined treatment of endoscopic hemostasis0693 (0.385--1.248)0.222Recurrent bleeding1.974 (1.075-- 3.623)0.0281.601 (0.781--3.282)0.906Antibiotic prophylaxis0.346 (0.167--0.719)0.0040.377 (0.180--0.786)0.009Abbreviations: *CI*, confidence interval; *COPD*, chronic obstructive pulmonary disease; *CVD*, Cardiovascular disease; *ESRD*, end-stage renal disease; *MELD*, Model for End-Stage Liver Disease; *NSAID*, nonsteroidal anti-inflammatory drug; *WBC*, white blood cells; *Hb*, hemoglobin; *PLT*, platelet count; *PT*, prothrombin time

In-hospital death occurred in 40 patients (17 %). Causes of death were hypovolemic shock in 8 patients (1 in the antibiotic group and 7 in control group), sepsis in 10 patients (3 and 7 patients, respectively) and multiple organ failure in 22 patients (8 and 14 patients, respectively). There was no significant difference in mortality during hospitalization between patients treated with intravenous ceftriaxone (*n* = 12, 13.6 %) and those in the control group (*n* = 28, 19 %). The observed survival was virtually identical for both groups (*p* = 0.112; Table [1](#Tab1){ref-type="table"}). The results of the univariate and multivariate analyses for independent risks of death after acute PUB are summarized in Table [4](#Tab4){ref-type="table"}. The results of univariate analysis showed that decompensated cirrhosis, total bilirubin level, Rockall score, MELD score, Child-Pugh score, bacterial infection, and recurrent bleeding were associated with an increased risk of death. In multivariate analysis, the in-hospital mortality was remarkably dependent on Rockall score (HR = 1.884; 95 % CI = 1.477--2.404; p \<0.001) and recurrent bleeding (HR = 2.796; 95 % CI = 1.473--5.306; *p* = 0.002).Table 4Univariate and multivariate analysis of potential risk factors for death in patients with peptic ulcer bleeding after endoscopic treatmentVariableUnivariate analysisMultivariate analysisHazard ratio (95 % CI)*p*-valueHazard ratio (95 % CI)*p*-valueAge0.981 (0.958--1.004)0.112Male gender2.046 (0.902--4.639)0.087Etiology of liver cirrhosis  Alcoholic1.188 (0.577--2.455)0.641  Viral hepatitis1.023 (0.722--1.488)0.887  Cryptogenic0.713 (0.366 --1.392)0.322Decompensated cirrhosis2.112 (1.014--4.402)0.0461.259 (0.497--3.188)0.627Rockall score1.638 (1.327--2.022)\<0.0011.884 (1.477--2.404)\<0.001MELD score1.049 (1.007--1.093)0.0230.945 (0.875--1.020)0.417Child-Pugh score1.321 (1.126--1.548)0.0011.252 (0.915--1.712)0.163Other comorbidities  Diabetes mellitus1.163 (0.825--1.639)0.388  Hypertension0.826 (0.437--1.562)0.555  CVD1.656 (0.396--6.924)0.490  Stroke0.830 (0.194--3.542)0.801  ESRD1.462 (0.445--4.808)0.532  COPD0.495 (0.145--1.683)0.260Use of NSAID or aspirin1.381 (0.765--2.493)0.284Smoking1.040 (0.739--1.465)0.820Active alcoholism1.453 (0.771--2.739)0.248WBC (10^9^/l)10.737Hb (g/dl)0.941 (0.809--1.095)0.431PLT (10^9^/l)0.997 (0.992--1.002)0.211PT (second)1.355 (0.823--2.232)0.232Creatinine (mg/dl)1.003 (0.857--1.174)0.972Albumin (g/l)0.906 (0.555--1.479)0.692Total bilirubin1.056 (1.004--1.111)0.0330.987 (0.916--1.063)0.731Blood units transfused0.989 (0.961--1.018)0.468Hypovolemic shock on admission1.184 (0.420--3.341)0.750High risk bleeding stigmata at ulcer base1.103 (0.407--2.989)0.848Time (h), bleeding to endoscopic treatment0.972 (0.936--1.010)0.143Combined treatment of endoscopic hemostasis0.966 (0.485--1.926)0.922Bacterial infection1.770 (0.945--3.318)0.075Recurrent bleeding2.412 (1.292--4.501)0.0062.796 (1.473--5.306)0.002Antibiotic prophylaxis0.582 (0.293--1.151)0.121Abbreviations: *CI*, confidence interval; *COPD*, chronic obstructive pulmonary disease; *CVD*, Cardiovascular disease; *ESRD*, end-stage renal disease; *MELD*, Model for End-Stage Liver Disease; *NSAID*, nonsteroidal anti-inflammatory drug; *WBC*, white blood cells; *Hb*, hemoglobin; *PLT*, platelet count; *PT*, prothrombin time

Subgroup analytical result for compensated and decompensated patients {#Sec9}
---------------------------------------------------------------------

By using the Kaplan--Meier approach, the administration of prophylactic antibiotics was not associated with significant differences in in-hospital mortality between our cohort (13.6 % vs. 19 %, *p* = 0.112 by log-rank test; Fig. [1](#Fig1){ref-type="fig"}). On the other hand, we observed that the in-hospital mortality was 28.6 % in patients with decompensated cirrhosis and 7.7 % in patients with compensated cirrhosis (p \<0.001) following acute PUB. Because the lack of a beneficial effect may be related to the severity of liver disease, we conducted a sub-analysis on the basis of liver decompensation among these cirrhotic patients. The observed in-hospital mortality was virtually identical for both groups of patients with baseline compensated cirrhosis (93.2 % vs. 91.9 %, *p* = 0.830 by log-rank test; Fig. [2](#Fig2){ref-type="fig"}). However, the administration of prophylactic antibiotics showed significantly reduction of in-hospital mortality of patients with baseline decompensated cirrhosis compared to those without antibiotic prophylaxis (79.5 % vs. 65.6 %, *p* = 0.034 by log-rank test) after subgroup analysis (Fig. [3](#Fig3){ref-type="fig"}). The predictive risk factor associated with in-hospital death among decompensated cirrhotic patients was Rockall score (HR, 1.623; 95 % CI, 1.204--2.187; *p* = 0.001). Antibiotic prophylaxis has a protective role for in-hopital death in these patients (HR, 0.395; 95 % CI, 0.173--0.899; *p* = 0.027). For compensated cirrhotic patient, Rockall score (HR, 1.633; 95 % CI, 1.103--2.417; *p* = 0.014) and recurrent bleeding (HR, 3.684; 95 % CI, 1.040--13.05; *p* = 0.044) were the predictive factors associated with in-hospital death (Table [5](#Tab5){ref-type="table"}).Fig. 1Actuarial probability of remaining survival in all cirrhotic patients after endoscopic interventions for the ceftriaxone group (antibiotic prophylaxis group) and the nil- antibiotic prophylaxis group (control group)Fig. 2Actuarial probability of remaining survival at different stages of cirrhotic patients (compensated liver cirrhosis). There was a similar probability of survival between compensated patients who were prescribed with intravenous ceftriaxone and those without antibiotic prophylaxis (*p* = 0.830 by log-rank test)Fig. 3Actuarial probability of remaining survival at different stages of cirrhotic patients (decompensated liver cirrhosis). A significantly higher probability of remaining survival was observed in those who were prescribed with intravenous ceftriaxone than those without antibiotic prophylaxis (*p* = 0.034 by log-rank test)Table 5Univariate and multivariate analysis of potential risk factors for mortality with peptic ulcer bleeding after endoscopic treatment at different clinical stages of cirrhotic patients (subgroup analysis)VariableCompensated liver cirrhosis (*N* = 130)Decompensated liver cirrhosis (*N* = 105)Univariate analysisMultivariate analysisUnivariate analysisMultivariate analysis*p*-valueHazard ratio (95 % CI)*p*-value*p*-valueHazard ratio (95 % CI)*p*-valueAge0.7530.115Male gender0.1400.351Etiology of liver cirrhosis  Alcoholic0.1360.639  Viral hepatitis0.2810.422  Cryptogenic0.6440.482Rockall score0.0141.633 (1.103--2.417)0.0140.0011.623 (1.204--2.187)0.001MELD score0.7130.151Child-Pugh score0.2360.0131.088 (0.855--1.384)0.492Other comorbidities  Diabetes mellitus0.3940.477  Hypertension0.3520.831  CVD0.7290.195  Stroke0.1680.450  ESRD0.9860.128  COPD0.5840.157Use of NSAID or aspirin0.3860.128Smoking0.6290.975Active alcoholism0.5330.177WBC (10^9^/l)0.4280.880Hb (g/dl)0.9210.463PLT (10^9^/l)0.7960.375PT (second)0.8980.597Creatinine (mg/dl)0.7660.869Albumin (g/l)0.5170.955Total bilirubin0.4500.167Blood units transfused0.7940.309Hypovolemic shock on admission0.3960.751High risk bleeding stigmata at ulcer base0.5930.676Time (h), bleeding to endoscopic treatment0.7340.085Combined treatment of endoscopic hemostasis0.2290.538Bacterial infection0.3270.224Recurrent bleeding0.0433.684 (1.040--13.05)0.0440.096Antibiotic prophylaxis0.8300.0420.395 (0.173--0.899)0.027Abbreviations: *CI*, confidence interval; *COPD*, chronic obstructive pulmonary disease; *CVD*, Cardiovascular disease; *ESRD*, end-stage renal disease; *MELD*, Model for End-Stage Liver Disease; *NSAID*, nonsteroidal anti-inflammatory drug; *WBC*, white blood cells; *Hb*, hemoglobin; *PLT*, platelet count; *PT*, prothrombin time

Discussion {#Sec10}
==========

Multiple factors contribute to the infection of cirrhotic patients with upper gastrointestinal bleeding. Cirrhotic patients usually have host defense defects against bacterial infection \[[@CR16]\]. Furthermore, hypovolemia has been reported to increase intestinal bacterial translocation and depress reticuloendothelial system activity \[[@CR17], [@CR18]\]. In addition, patients with decompensated cirrhosis have more frequent episodes of infection than those with compensated liver disease \[[@CR19]\]. Bacterial infection is associated with failure to control bleeding and patients with recurrent bleeding episodes \[[@CR20]\]. An increase in portal pressure and changes in hemostasis induced by infection have been suggested as possible mechanisms \[[@CR1], [@CR21]\]. It has been suggested that intestinal bacterial translocation plays an important role in the pathogenesis of many infections. A meta-analysis of 12 trials comprising a total of 1241 patients with cirrhosis and gastrointestinal bleeding demonstrated that antibiotic prophylaxis significantly decreased the incidence of bacterial infections, re-bleeding, length of hospitalization, and mortality \[[@CR22]\]. Currently, antibiotic prophylaxis is the standard care for cirrhotic patients with acute variceal bleeding but the prescription of antibiotic prophylaxis in cirrhotic patient with PUB has not been well documented. In order to address this particular issue in cirrhotic patients with PUB, we conducted this hospital-based cohort study for further clarification.

The results of the current study proved the benefit of antibiotic prophylaxis for bleeding peptic ulcers in cirrhotic patients with only 9 of the 88 patients (10.8 %) included in the antibiotic group developing bacterial infections during hospitalization. On the other hand, 37 of the 147 patients (25.2 %) in the control group suffered from a greater number of infectious events. In the multivariate analysis, higher Child-Pugh score, active alcoholism, and no antibiotic prophylaxis were significant predictors of infection development. Bacterial infections have been observed more frequently in Child-Pugh's C patients than in those with Child-Pugh's A or B \[[@CR23]\] and active alcoholism can increase host susceptibility to bacterial infection, probably owing to the immunocompromised status following liver decompensation \[[@CR24]\]. The bottom line is, the most common pathogens cultured in cirrhotic patients are gram-negative bacilli \[[@CR15], [@CR20]\]. The hypothesis behind this could be the onset of infection by intestinal bacterial translocation. In our study, gram-positive cocci accounted for 28.6 % of infections. This was probably because cirrhotic patients with upper gastrointestinal bleeding tended to receive multiple sessions of diagnostic and therapeutic invasive procedures, which in turn resulted in infections with gram-positive cocci \[[@CR25], [@CR26]\].

Overall, the ulcer rebleeding rate observed in the current study (22.3 %) which was higher than those reported in non-cirrhotic patients (3.2 %) \[[@CR27]\] or in cirrhotic patients (7 %) \[[@CR28]\]. The higher rebleeding events may be explained by the occurrence of a greater number of high risk bleeding stigmata identified in all of our patients with PUB (Forrest Ia, Ib: 51.9 % and Forrest IIa, IIb: 42.4 %) compared with those reported by the Marmo and Rudler groups \[[@CR27], [@CR28]\]. However, we observed that rebleeding and mortality do not seem to be associated with time to endoscopy. Although patients in the present study received endoscopy within 24 h, mortality remains high compared to patients without cirrhosis in the literature \[[@CR29]\]. The predictors for rebleeding were: a higher Rockall score, more units of blood transfused, and no antibiotic prophylaxis. Again, current study proved the importance of administrating prophylactic antibiotics is crucial in preventing rebleeding in cirrhotic patients. Although presence of high risk bleeding stigmata is well-established risk factor for peptic ulcer bleeding, we didn't find significantly correlation with rebleeding. Several factors might contribute to the discrepant results. First, it is possible that this retrospective analysis depended heavily on the completeness of the medical records and bias could exist. However, we reviewed endoscopic images or videos to determine the severity of the ulcer involved if uncertain chart description of ulcer morphology was encountered. Second, it was probably due to most ulcers belonged to high stigmata (Forrest Ia, Ib: 50.2 % and Forrest IIa, IIb: 38.7 %) in all of our enrolled patients. In fact, current guidelines do not recommend hemostatic therapy for patients with low-risk stigmata, such as those ulcers with a clean base (Forrest III) or ulcers with flat spots (Forrest IIc), and even recommend early discharge in selected patients with a low risk of rebleeding after endoscopic evaluation.

However, our study failed to show a significant difference in mortality or reduced length of hospital stay between patients who received prophylactic antibiotics and the control group. Probably, other factors such as requirement for mechanical ventilation, length of stay in intensive care unit, multiple organ dysfunction, and underlying comorbidities contributed to longer hospital stays and could be important determinants other than prophylactic antibiotic administration. Our study also clearly showed the increased mortality of patients with decompensated cirrhosis compared to those with compensated cirrhosis, with a quadrupling tripling of mortality risk (28.6 % vs. 7.7 %). Moreover, there was still an increased mortality of patients with decompensated cirrhosis compared with compensated cirrhosis even among patients with antibiotic prophylaxis (20.5 % vs. 6.8 %). Overall, the mortality rate in this study was 17 %. This was higher than those reported in previous studies of PUB \[[@CR30]\]. This was not surprising because 44.7 % of our patients had decompensated cirrhosis. Patients with cirrhosis who develop PUB were at increased risk of mortality, and the risk appeared to increase further as patients progressed from compensated to decompensated cirrhosis. This could be due to the fact that patients with decompensated cirrhosis have an increased risk of developing sepsis, multiple organ failure, and death \[[@CR31]\]. To our knowledge, our study was the first to compare the outcomes in cirrhotic patients with or without liver compensation who received antibiotic prophylaxis for PUB. Because no beneficial effect of antibiotic prophylaxis may be attributed to the severity of liver disease, we decided to perform a subgroup analysis on the basis of liver compensation by dividing our patients into 2 subgroups. Our results revealed an important message that intravenous ceftriaxone is only of benefit in reducing mortality in decompensated cirrhotic patients with peptic ulcer hemorrhage.

Mortality occurred in 13.6 % and 19 % of patients with or without antibiotic prophylaxis respectively. Only 20 % of the deaths were directly related to the bleeding episode, whilst the remaining deaths were associated with sepsis (*n* = 40, 25 %) and multi-organ failure (*n* = 22, 55 %). Despite substantial improvement in PUB management, the mortality in cirrhotic patients remains high, especially among patients with advanced liver cirrhosis \[[@CR32], [@CR33]\]. In a recently published study of 10,428 patients with non-variceal upper gastrointestinal bleeding in non-cirrhotic patients, death was associated with causes directly related to the bleeding episode in only 29 % of cases whilst in the remaining cases, co-morbidity played a fundamental role \[[@CR34]\]. In other words, most PUB-linked deaths are not directly caused by the bleeding ulcer itself. This probably explains why routine antibiotic prophylaxis after gastrointestinal bleeding, even though it significantly reduces the incidence of bacterial infections, does not significantly affect the mortality rate. As most mortality occurs as a result of multi-organ failure, this suggests that improved treatments and supportive care should be provided to prevent sepsis complications and key organ failure. On the other hand, three patients died from uncertain causes soon after endoscopy and they were excluded from study. The causes of mortality could not be determined whether they were procedure-related (suffocation, aspiration pneumonia, bowel trauma, incomplete endoscopic hemostasis, as extra), bleeding-related or other causes such as acute myocardial infarction, brain stroke, perforated peptic ulcer, as extra. Therefore, we excluded patients who die within 24 h due to unable to analyses the cause of mortality.

The Rockall score was found to be an independent predictor of in-hospital mortality \[[@CR11]\]. It makes séance as it includes both clinical and endoscopic criteria to predict the risk of rebleeding and death. The bottom line is, we used the MELD score, the Child-Pugh classification, and the Rockall's risk scoring system to assess our patients but mortality was surprisingly not related to the severity of liver dysfunction as expressed by either the MELD score or the Child-Pugh classification. Only Rockall scores were associated with rebleeding and death. The effectiveness of the Rockall score as a predictor of in-hospital death in cirrhotic patients with PUB proved to be similar to that reported in non-cirrhotic patients \[[@CR35]\].

A major strength of this study is that it was a well-defined consecutive registered study cohort treated by a standard endoscopic intervention. Patients who received antibiotic prophylaxis were defined as antibiotic group and those who not received were used as historical control. To provide the highest possible level of uniformity and to minimize differences in the entry, only patients who received their initial and subsequent treatment in our unit were studied. The robustness of this study is enhanced by the restriction of subjects to patients without an apparent source of infection at first bleeding episode, strict exclusion criteria and the complete follow-up of the cohort. The use of rebleeding, infection and death as the main outcomes provided consistent and objective endpoints in the study. Unlike other studies, which have included patients at differing disease stages without separate analyses, our study did evaluate the impact of liver function on the efficacy of antibiotics.

Current study encountered some limitations. First, the sample size was small and a single center cohort study. Certain selection biases could exist and must be cautious in extrapolating the results. Multicenter data with a larger sample size is mandatory. Second, the authors also served as data abstractors and could have been biased because they were not blinded which was not possible in this retrospective cohort study. Therefore, exposure bias might be considered a limitation of this study. Third, survivor bias may have occurred in which surviving patients who probably had more opportunities to receive intensive care, such as ventilator support, hemodialysis, repeated endoscopic hemostasis and more blood product transfusions.

Those patients who belonged to control group were enrolled between January 1, 2008, and December 31, 2009. The antibiotic group has been routine practice to prescribe prophylactic antibiotics to cirrhotic patients with gastrointestinal bleeding in our hospital since 2010. This minimized bias in our results, because both cohorts were enrolled according to identical treatment protocol adhering to our hospital policy in our daily practices for PUB population even though during the different period.

Conclusions {#Sec11}
===========

This study confirmed the beneficial effects of antibiotic prophylaxis in patients with cirrhosis following APU with the reduced infections and rebleeding events. The study also suggests that antibiotic prophylaxis could improve survival in decompensated cirrhotic patients following acute PUB. The Rockall score was the strongest predictive factor of in-hospital mortality. Further studies directed to explore ways to improve the overall outcome of cirrhotic patients with PUB are mandatory.

PUB

:   Peptic ulcer bleeding

NSAID

:   Non-steroid anti-inflammatory drugs

HBsAg

:   Hepatitis B antigen

Anti-HCV

:   Hepatitis C antibody

HR

:   Hazard ratio

EV

:   Esophageal varices

GV

:   Gastric varices
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:   Model for end-stage liver disease

ESRD

:   End stage renal disease
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:   Chronic obstructive pulmonary disease
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